Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 2
2019 1
2020 1
2021 1
2022 8
2023 9
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study.
Puthanakit T, Prompetchara E, Gatechompol S, Ketloy C, Thitithanyanont A, Jongkaewwattana A, Buranapraditkun S, Ubolyam S, Kerr SJ, Sophonphan J, Apornpong T, Kittanamongkolchai W, Siwamogsatham S, Sriplienchan S, Patarakul K, Theerawit T, Promsena P, Nantanee R, Manomaisantiphap S, Chokyakorn S, Hong L, Samija M, Montefiori DC, Gao H, Eaton A, Wijagkanalan W, Alameh MG, Weissman D, Ruxrungtham K; ChulaVac001-Phase 2 study team. Puthanakit T, et al. Sci Rep. 2024 Jan 29;14(1):2373. doi: 10.1038/s41598-023-49653-6. Sci Rep. 2024. PMID: 38287068 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, Boonsathorn S, Chantasrisawad N, Sudjaritruk T, Niyomnaitham S, Senawong S, Srisutthisamphan K, Quan Toh Z, Rungmaitree S, Nanthapisal S, Phanthanawiboon S, Khantee P, Techasaensiri C, Hirankarn N, Pangprasertkul S, Chokephaibulkit K. Wittawatmongkol O, et al. Among authors: srisutthisamphan k. Vaccine. 2023 Sep 15;41(40):5834-5840. doi: 10.1016/j.vaccine.2023.08.021. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586956 Free article. Clinical Trial.
Pseudotyped zoonotic thogotoviruses exhibit broad entry range in mammalian cells.
Thamamongood T, Jengarn J, Muangsanit P, Petpiroon N, Srisutthisamphan K, Attasombat K, Wongwanakul R, Aueviriyavit S, Laohathai S, Jongkaewwattana A, Teeravechyan S. Thamamongood T, et al. Among authors: srisutthisamphan k. Virology. 2024 Jan;589:109914. doi: 10.1016/j.virol.2023.109914. Epub 2023 Oct 28. Virology. 2024. PMID: 37931589 Free article.
Human BST2 inhibits rabies virus release independently of cysteine-linked dimerization and asparagine-linked glycosylation.
Tanwattana N, Wanasen N, Jantraphakorn Y, Srisutthisamphan K, Chailungkarn T, Boonrungsiman S, Lumlertdacha B, Lekchareonsuk P, Kaewborisuth C. Tanwattana N, et al. Among authors: srisutthisamphan k. PLoS One. 2023 Nov 3;18(11):e0292833. doi: 10.1371/journal.pone.0292833. eCollection 2023. PLoS One. 2023. PMID: 37922253 Free PMC article.
Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations.
Niyomnaitham S, Atakulreka S, Wongprompitak P, Copeland KK, Toh ZQ, Licciardi PV, Srisutthisamphan K, Jansarikit L, Chokephaibulkit K. Niyomnaitham S, et al. Among authors: srisutthisamphan k. Front Immunol. 2023 Jan 17;13:1080791. doi: 10.3389/fimmu.2022.1080791. eCollection 2022. Front Immunol. 2023. PMID: 36733395 Free PMC article. Clinical Trial.
Hsp90 interacts with multiple dengue virus 2 proteins.
Srisutthisamphan K, Jirakanwisal K, Ramphan S, Tongluan N, Kuadkitkan A, Smith DR. Srisutthisamphan K, et al. Sci Rep. 2018 Mar 9;8(1):4308. doi: 10.1038/s41598-018-22639-5. Sci Rep. 2018. PMID: 29523827 Free PMC article.
Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera.
Viriyakitkosol R, Wanitchang A, Srisutthisamphan K, Saenboonreung J, Boonkrai C, Pisitkun T, Jongkaewwattana A. Viriyakitkosol R, et al. Among authors: srisutthisamphan k. Front Immunol. 2023 Aug 1;14:1219546. doi: 10.3389/fimmu.2023.1219546. eCollection 2023. Front Immunol. 2023. PMID: 37593745 Free PMC article.
Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers.
Imsuwansri T, Jongthitinon T, Pojdoung N, Meesiripan N, Sakarin S, Boonkrai C, Wongtangprasert T, Phakham T, Audomsun T, Attakitbancha C, Saelao P, Muanwien P, Tian MT, Tongchusak S, Sangruji B, Wannigama DL, Sawangmake C, Rodprasert W, Le QD, Purbantoro SD, Vasuntrarak K, Nantavisai S, Sirilak S, Uppapong B, Sapsutthipas S, Trisiriwanich S, Somporn T, Usoo A, Mingngamsup N, Phumiamorn S, Aumklad P, Arunprasert K, Patrojanasophon P, Opanasopit P, Pesirikan N, Nitisaporn L, Pitchayakorn J, Narkthong T, Mahong B, Chaiyo K, Srisutthisamphan K, Viriyakitkosol R, Aeumjaturapat S, Jongkaewwattana A, Bunnag S, Pisitkun T. Imsuwansri T, et al. Among authors: srisutthisamphan k. Sci Rep. 2023 Sep 20;13(1):15648. doi: 10.1038/s41598-023-42539-7. Sci Rep. 2023. PMID: 37730833 Free PMC article. Clinical Trial.
Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, Pichyangkul S, Taepavarapruk P, Praserthsee W, Malaivijitnond S, Manopwisedjaroen S, Thitithanyanont A, Srisutthisamphan K, Jongkaewwattana A, Tomai M, Fox CB, Taychakhoonavudh S. Phoolcharoen W, et al. Among authors: srisutthisamphan k. Vaccine. 2023 Apr 24;41(17):2781-2792. doi: 10.1016/j.vaccine.2023.03.027. Epub 2023 Mar 21. Vaccine. 2023. PMID: 36963999 Free PMC article.
27 results